New ALS drug prosetin enters first human safety trials
NCT ID NCT05279755
First seen May 01, 2026 · Last updated May 24, 2026 · Updated 4 times
Summary
This early-stage study tests whether a new drug, prosetin, is safe for people with ALS and healthy volunteers. Researchers will give different doses to find the safest amount and see how the body processes the drug. The study involves about 72 people and is a first step before larger trials can determine if prosetin helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
The Neuro - Montréal Neurological Institute-Hospital
Montreal, Quebec, H3A 2B4, Canada
-
University Medical Center Utrecht
Utrecht, Utrecht, 3584 CX, Netherlands
-
Worldwide Clinical Trials Early Phase Services
San Antonio, Texas, 78217, United States
Conditions
Explore the condition pages connected to this study.